simendan has been researched along with Sepsis in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (22.22) | 29.6817 |
| 2010's | 15 (55.56) | 24.3611 |
| 2020's | 6 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Chen, WT; Lei, YY; Lin, XF; Liu, DH; Liu, YY; Ning, YL; Xian, SX; Yang, ZQ | 1 |
| Bonderski, V; Krishnan, K; Rech, MA; Tednes, P; Wassermann, TB | 1 |
| Cheng, Q; Guo, J; Zhang, X; Zhu, Y | 1 |
| Chen, N; Cui, N; Ding, XX; Li, N; Sun, T; Wang, SH; Yu, ZB; Zhang, N | 1 |
| Fang, X; Huang, P; Jin, H; Liu, F; Ma, Z; Wang, S | 1 |
| Guan, Q; Huang, D; Li, A; Li, B; Qin, J; Zhang, C; Zhang, X | 1 |
| Hashimoto, Y; Hishikawa, H; Kaibori, M; Matsushima, H; Nishizawa, M; Okumura, T; Sakaguchi, T | 1 |
| Baidya, DK; Bhattacharjee, S; Maitra, S; Soni, KD | 1 |
| Chang, W; Xie, JF; Xu, JY; Yang, Y | 1 |
| Hattori, K; Hattori, Y; Iguchi, K; Matsuda, N; Misawa, H; Nagata, T; Sakai, M; Sakamoto, T; Suzuki, T; Tomita, K; Watanabe, Y; Yamashita, S; Yokoo, H; Yoshimura, N | 1 |
| García-García, AE; Mena-Arceo, RG; Ñamendys-Silva, SA; Rojo Del Moral, O | 1 |
| Chen, Z; Sun, Y; Yang, F; Zhao, LN | 1 |
| Gordon, A; McAuley, DF; O'Kane, C; Prevost, AT; Santhakumaran, S; Shankar-Hari, M | 1 |
| Chang, XN; Chen, Y; Dong, CM; Feng, F; Li, M; Yuan, JJ | 1 |
| Bignami, E; De Luca, M; Di Tomasso, N; Frau, G; Landoni, G; Likhvantsev, V; Lomivorotov, V; Monaco, F; Oriani, A; Putzu, A; Zangrillo, A | 1 |
| Abedelzaher, LA; Hattori, K; Hattori, Y; Imaizumi, T; Matsuda, N; Ohashi, W; Sakamoto, T; Sakata, K; Takashina, M; Wang, Q; Yokoo, H | 1 |
| Angelini, GD; Belletti, A; Benedetto, U; Biondi-Zoccai, G; Landoni, G; Leggieri, C; Silvani, P; Zangrillo, A | 1 |
| Graetz, TJ; Hotchkiss, RS | 1 |
| Ahluwalia, D; Boost, KA; Dolfen, A; Hoegl, S; Hofstetter, C; Muhl, H; Revermann, M; Scheiermann, P; Zwissler, B | 1 |
| Eriksson, H; Salmenperä, M | 1 |
| Aydede, H; Erbüyün, K; Erhan, Y; Ok, G; Tekin, I; Tok, D; Türköz, E; Vatansever, S | 1 |
| Karvouniaris, M; Makris, D; Papanikolaou, J; Zakynthinos, E | 1 |
| Bent, F; Plaschke, K | 1 |
| Bouali, R; Dubois, MJ; Verdant, CL | 1 |
| Barraud, D; Damy, T; Faivre, V; Gayat, E; Heymes, C; Mebazaa, A; Payen, D; Shah, AM; Welschbillig, S | 1 |
| De Keulenaer, B; Powell, BP | 1 |
| Ertmer, C; Pinto, BB; Rehberg, S; Westphal, M | 1 |
12 review(s) available for simendan and Sepsis
| Article | Year |
|---|---|
Levosimendan versus dobutamine for sepsis-induced cardiac dysfunction: a systematic review and meta-analysis.
Topics: Disease-Free Survival; Dobutamine; Heart Diseases; Lactic Acid; Sepsis; Simendan; Stroke Volume; Survival Rate | 2021 |
Beyond the bundle: Clinical controversies in the management of sepsis in emergency medicine patients.
Topics: Angiotensin II; Ascorbic Acid; Crystalloid Solutions; Disease Management; Drug Therapy, Combination; Emergency Service, Hospital; Humans; Hydrocortisone; Randomized Controlled Trials as Topic; Sepsis; Shock, Septic; Simendan; Thiamine | 2022 |
A Meta-Analysis of the Effects of Levosimendan on Cardiac Function and Outcomes in Patients with Sepsis.
Topics: Dobutamine; Humans; Hydrazones; Pyridazines; Sepsis; Shock, Septic; Simendan; Stroke Volume; Ventricular Function, Left | 2023 |
Meta-Analysis of the Efficacy of Levosimendan in the Treatment of Severe Sepsis Complicated with Septic Cardiomyopathy.
Topics: Adult; Calcium; Cardiomyopathies; Cardiotonic Agents; Humans; Hydrazones; Multiple Organ Failure; Pyridazines; Sepsis; Simendan; Stroke Volume; Ventricular Function, Left | 2023 |
Levosimendan does not provide mortality benefit over dobutamine in adult patients with septic shock: A meta-analysis of randomized controlled trials.
Topics: Adult; Cardiotonic Agents; Dobutamine; Humans; Hydrazones; Intensive Care Units; Norepinephrine; Pyridazines; Randomized Controlled Trials as Topic; Sepsis; Shock, Septic; Simendan | 2017 |
Effect of levosimendan on mortality in severe sepsis and septic shock: a meta-analysis of randomised trials.
Topics: Cardiotonic Agents; Humans; Hydrazones; Pyridazines; Randomized Controlled Trials as Topic; Sepsis; Shock, Septic; Simendan | 2018 |
Levosimendan as a new force in the treatment of sepsis-induced cardiomyopathy: mechanism and clinical application.
Topics: Cardiomyopathies; Cardiotonic Agents; Cardiotoxicity; Humans; Prognosis; Sepsis; Simendan | 2019 |
Levosimendan does not reduce the mortality of critically ill adult patients with sepsis and septic shock: a meta-analysis.
Topics: Critical Illness; Female; Humans; Male; Sepsis; Shock, Septic; Simendan | 2019 |
Levosimendan reduces mortality in patients with severe sepsis and septic shock: A meta-analysis of randomized trials.
Topics: Cardiotonic Agents; Dobutamine; Female; Humans; Hydrazones; Male; Middle Aged; Norepinephrine; Pyridazines; Randomized Controlled Trials as Topic; Sepsis; Shock, Septic; Simendan | 2015 |
The effect of vasoactive drugs on mortality in patients with severe sepsis and septic shock. A network meta-analysis of randomized trials.
Topics: Arginine Vasopressin; Cardiotonic Agents; Dobutamine; Dopamine; Epinephrine; Humans; Hydrazones; Network Meta-Analysis; Norepinephrine; Odds Ratio; Pyridazines; Randomized Controlled Trials as Topic; Sepsis; Shock, Septic; Simendan; Treatment Outcome; Vasoconstrictor Agents; Vasopressins | 2017 |
Levosimendan in perioperative and critical care patients.
Topics: Animals; Cardiopulmonary Bypass; Critical Care; Heart; Humans; Hydrazones; Myocardial Contraction; Perioperative Care; Potassium Channels; Pyridazines; Sepsis; Shock, Cardiogenic; Simendan; Systole; Vasodilation | 2009 |
Role of levosimendan in sepsis and septic shock.
Topics: Animals; Calcium; Dose-Response Relationship, Drug; Drug Interactions; Endotoxemia; Heart Failure; Humans; Hydrazones; Potassium Channels; Pyridazines; Sepsis; Shock, Septic; Simendan | 2008 |
1 trial(s) available for simendan and Sepsis
| Article | Year |
|---|---|
Efficacy of Levosimendan in the Treatment of Patients With Severe Septic Cardiomyopathy.
Topics: Cardiomyopathies; Cardiotonic Agents; Dobutamine; Humans; Hydrazones; Norepinephrine; Prospective Studies; Pyridazines; Sepsis; Shock, Septic; Simendan; Single-Blind Method; Stroke Volume; Ventricular Function, Left | 2023 |
14 other study(ies) available for simendan and Sepsis
| Article | Year |
|---|---|
Comparison of dobutamine and levosimendan for treatment of sepsis-induced cardiac dysfunction: A protocol for systematic review and meta-analysis.
Topics: Dobutamine; Heart Diseases; Humans; Meta-Analysis as Topic; Sepsis; Simendan; Systematic Reviews as Topic | 2022 |
Levosimendan pretreatment improves survival of septic rats after partial hepatectomy and suppresses iNOS induction in cytokine-stimulated hepatocytes.
Topics: Animals; Cytokines; Hepatectomy; Hepatocytes; Lipopolysaccharides; Male; Nitric Oxide; Nitric Oxide Synthase Type II; Rats; Rats, Sprague-Dawley; Sepsis; Simendan; Vasodilator Agents | 2019 |
Cardioprotective and functional effects of levosimendan and milrinone in mice with cecal ligation and puncture-induced sepsis.
Topics: Animals; Calcium; Cardiotonic Agents; Cecum; Cytokines; Ligation; Male; Mice, Inbred BALB C; Milrinone; Myocardium; Myocytes, Cardiac; Sepsis; Simendan; Ventricular Function, Left; Wounds, Penetrating | 2018 |
Organ Function Assessment, Prevention, and Outcomes in Critically Ill Patients with Sepsis.
Topics: Critical Illness; Humans; Multiple Organ Failure; Organ Dysfunction Scores; Sepsis; Simendan | 2018 |
Heterogeneity of treatment effect by baseline risk of mortality in critically ill patients: re-analysis of three recent sepsis and ARDS randomised controlled trials.
Topics: Adult; Aged; Anti-Inflammatory Agents; APACHE; Cardiotonic Agents; Critical Illness; Female; Guideline Adherence; Hospital Mortality; Humans; Hydrocortisone; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intensive Care Units; Male; Middle Aged; Randomized Controlled Trials as Topic; Respiratory Distress Syndrome; Sepsis; Simendan; Simvastatin; Treatment Outcome; Vasoconstrictor Agents; Vasopressins | 2019 |
Anti-Inflammatory Profile of Levosimendan in Cecal Ligation-Induced Septic Mice and in Lipopolysaccharide-Stimulated Macrophages.
Topics: Animals; Anti-Inflammatory Agents; Biopsy, Needle; Blotting, Western; Cecum; Cells, Cultured; Cytokines; Disease Models, Animal; Echocardiography; Enzyme-Linked Immunosorbent Assay; Hydrazones; Immunohistochemistry; Injections, Intravenous; Ligation; Lipopolysaccharides; Macrophages; Male; Mice; Mice, Inbred BALB C; Pyridazines; Random Allocation; Real-Time Polymerase Chain Reaction; Reference Values; Sepsis; Simendan; Statistics, Nonparametric; Survival Rate | 2015 |
Sepsis: Preventing organ failure in sepsis - the search continues.
Topics: Humans; Multiple Organ Failure; Sepsis; Simendan; Treatment Failure; Vasodilator Agents | 2017 |
Effects of intravenous and inhaled levosimendan in severe rodent sepsis.
Topics: Administration, Inhalation; Animals; Humans; Hydrazones; Injections, Intraventricular; Models, Animal; Phosphodiesterase Inhibitors; Pyridazines; Random Allocation; Rats; Rats, Sprague-Dawley; Rodentia; Sepsis; Severity of Illness Index; Simendan; Survival Analysis; Treatment Outcome | 2009 |
Levosimendan up-regulates transforming growth factor-beta and smad signaling in the aorta in the early stage of sepsis.
Topics: Animals; Aorta; Blood Pressure; Dopamine; Hydrazones; Male; Pyridazines; Rats; Rats, Wistar; Sepsis; Simendan; Smad1 Protein; Smad2 Protein; Smad3 Protein; Transforming Growth Factor beta3; Tumor Necrosis Factor-alpha; Vasodilator Agents | 2010 |
Sepsis-associated takotsubo cardiomyopathy can be reversed with levosimendan.
Topics: Cardiotonic Agents; Echocardiography; Emergency Service, Hospital; Hemodynamics; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Sepsis; Simendan; Takotsubo Cardiomyopathy | 2012 |
Levosimendan's effect on platelet function in a rat sepsis model.
Topics: Animals; Blood Platelets; Disease Models, Animal; Hydrazones; Lipopolysaccharides; Male; Platelet Aggregation; Pyridazines; Rats; Sepsis; Simendan | 2013 |
15th Annual Congress of the European Society of Intensive Care Medicine, 29 September-2 October 2002, Barcelona, Spain: clinical research to improve outcome.
Topics: Acute Kidney Injury; Critical Care; Europe; Heart Failure; Humans; Hydrazones; Incidence; Intensive Care Units; Lung Volume Measurements; Outcome Assessment, Health Care; Phosphodiesterase Inhibitors; Positive-Pressure Respiration; Pyridazines; Renal Replacement Therapy; Sepsis; Simendan; Societies, Medical; Spain | 2003 |
Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinone.
Topics: Animals; Cardiotonic Agents; Diastole; Disease Models, Animal; Dobutamine; Heart Failure; Hydrazones; Lipopolysaccharides; Milrinone; Pyridazines; Rabbits; Sepsis; Simendan; Systole; Ventricular Function, Left | 2007 |
Levosimendan: a new option in acute septic cardiac failure?
Topics: Acute Disease; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Sepsis; Simendan | 2007 |